Quote: Inside Sloan-Kettering’s Zaltrap decision
Austin Frakt October 22, 2013
As soon as he heard that, Bach, who has been documenting the dizzying rise of cancer-drug prices since 2009, immediately jumped into an elevator to
As soon as he heard that, Bach, who has been documenting the dizzying rise of cancer-drug prices since 2009, immediately jumped into an elevator to
From a recent, systematic review by Nicole Steck and colleagues: @afrakt
If website woes necessitate a delay, no congressional authorization is required. Want the details? Of course you do! Go read them in the new Bloomberg
Seroprevalence of Herpes Simplex Virus Types 1 and 2—United States, 1999–2010: Background: Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are common infections with
One of this weekend’s worthwhile reads was Tyler Cowen’s NYT op-ed on the Affordable Care Act and the future of health reform. On Medicaid, he
O.K., you know what to do: Google “spurious correlation health.” You are immediately led to the tale of certain Pacific Islanders who long believed that having
Well over a week ago, a few wonks exchanged tweets with Harold and me about recommended health policy books. Below is a list built from
As is the case with epidemiologists, the fundamental challenge faced by economists — and a root cause of many disagreements in the field — is
How Product Standardization Affects Choice: Evidence from the Massachusetts Health Insurance Exchange by Keith Marzilli Ericson and Amanda Starc (National Bureau of Economic Research) Standardization
Our results suggest that some types of placebo treatments can be, on average, associated with greater improvements than others. Although our study cannot prove that
In the ACA, Congress chose market-based cost controls over measures that are common internationally, such as global budgets. Mandating coverage while requiring affordable premiums without
I do wish they’d stop delivering them. I mostly use them to get a bit of exercise as I haul them from the bottom of